Indegene Limited (IN:INDGN)
:INDGN
INDGN Stock Chart & Stats
₹522.25
₹9.00(1.45%)
At close: 4:00 PM EST
₹522.25
₹9.00(1.45%)
Day’s Range― - ―
52-Week Range₹414.90 - ₹632.10
Previous CloseN/A
Volume943.30K
Average Volume (3M)17.62K
Market Cap
₹114.19B
Enterprise Value₹111.99B
Total Cash (Recent Filing)₹12.68B
Total Debt (Recent Filing)₹2.10B
Price to Earnings (P/E)30.3
Beta0.48
Next Earnings
Jun 03, 2026EPS Estimate
4.5Next Dividend Ex-DateN/A
Dividend Yield0.38%
Share Statistics
EPS (TTM)4.30
Shares Outstanding240,807,970
10 Day Avg. Volume12,460
30 Day Avg. Volume17,622
Financial Highlights & Ratios
PEG Ratio1.56
Price to Book (P/B)5.26
Price to Sales (P/S)4.85
P/FCF Ratio33.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹525.00Price Target Upside0.53% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)21.14
Revenue Forecast (FY)₹41.80B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth (RevenueGrowth ~18% reported) indicates durable demand for Indegene's tech-enabled life-sciences services. Recurring, multi-year client programs and cross-selling across commercial, medical, analytics and platform offerings support predictable revenue expansion over the medium term.
Margin SustainabilityConsistently high gross and operating margins reflect a scalable, high-value services model with strong pricing power and operating leverage. This margin profile supports durable profitability as incremental digital and managed-service work typically carries higher margin and lower variable cost intensity over time.
Balance Sheet StrengthA substantial equity base and low leverage provide financial flexibility to invest in platforms, organic growth, or M&A, and to absorb client churn. Lower debt reduces refinancing risk and supports long-term stability of operations and client-facing investments in regulated healthcare markets.
Bears Say
Cash Flow VolatilityInconsistent FCF growth and swings in investing/financing cash flows reduce predictability of internally generated capital for platform development or acquisitions. Over several quarters this can constrain strategic initiatives and increase reliance on external funding for growth.
EBITDA Decline In 2025A marked EBITDA drop in 2025 signals potential operational headwinds—project mix shifts, pricing pressure, or one-time costs—that can impair margin resilience. If persistent, this undermines operating leverage and the company’s ability to reinvest in platforms and retain talent critical to service delivery.
Balance Sheet/Profit VolatilityVariability in liabilities and equity alongside net income inconsistencies increases forecasting risk and may affect credit terms with vendors or lenders. Structural volatility complicates long-term planning for investments, pricing, and contract commitments in regulated client environments.
Indegene Limited News
INDGN FAQ
What was Indegene Limited’s price range in the past 12 months?
Indegene Limited lowest stock price was ₹414.90 and its highest was ₹632.10 in the past 12 months.
What is Indegene Limited’s market cap?
Indegene Limited’s market cap is ₹114.19B.
When is Indegene Limited’s upcoming earnings report date?
Indegene Limited’s upcoming earnings report date is Jun 03, 2026 which is in 59 days.
How were Indegene Limited’s earnings last quarter?
Indegene Limited released its earnings results on Jan 29, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹5.15 by -₹0.85.
Is Indegene Limited overvalued?
According to Wall Street analysts Indegene Limited’s price is currently Undervalued.
Does Indegene Limited pay dividends?
Indegene Limited pays a Notavailable dividend of ₹2 which represents an annual dividend yield of 0.38%. See more information on Indegene Limited dividends here
What is Indegene Limited’s EPS estimate?
Indegene Limited’s EPS estimate is 4.5.
How many shares outstanding does Indegene Limited have?
Indegene Limited has 240,807,970 shares outstanding.
What happened to Indegene Limited’s price movement after its last earnings report?
Indegene Limited reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹5.15. Following the earnings report the stock price went down -1.262%.
Which hedge fund is a major shareholder of Indegene Limited?
Currently, no hedge funds are holding shares in IN:INDGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Indegene Limited
Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.
INDGN Stock 12 Month Forecast
Average Price Target
₹525.00
▲(0.53% Upside)
Technical Analysis
ITI Limited
―
KPIT Technologies Limited
―
Mphasis Limited
―
Tata Elxsi Limited
―
Tech Mahindra Limited
―